News Release Details
Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
"We are delighted to welcome Neil to our team and look forward to leveraging his deep industry experience as the company prepares for the potential launch of VP-102 for molluscum contagiosum," commented
Mr. DeHenes brings to Verrica extensive experience in end-to-end commercialization support across the design, evaluation, implementation, and execution of channel strategy, patient services, co-pay offerings, third party logistics, and government program operations. He was the Life Sciences Commercial Strategy Lead at Deloitte Advisory where he provided executive oversight and supervision on all commercial strategy engagements within Deloitte’s Life Science and Healthcare sector. Prior to
About
Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company is currently advancing its lead product VP-102, a proprietary topical drug device combination therapy containing a novel topical solution of 0.7% cantharidin for the treatment of molluscum contagiosum and verruca vulgaris (common warts). Verrica is also currently evaluating and prioritizing other potential indications for VP-102 and the company’s proprietary topical solutions of cantharidin. Verrica is headquartered in
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential launch of VP-102 for molluscum contagiosum. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Verrica’s Quarterly Report on Form 10-Q for the quarter ended
Contacts:
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com
Managing Director
Westwicke Partners
415.513.1284
patti.bank@westwicke.com
Source: Verrica Pharmaceuticals Inc.